Health-Related Quality of Life 1 Year After Allogeneic or Autologous Stem-Cell Transplantation: A Prospective Study
- 1 February 1999
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (2) , 706
Abstract
PURPOSE: To evaluate health-related quality of life (HRQOL) in adults treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem-cell transplantation 1 year after transplantation, using data from concurrent lymphoma patients receiving combination chemotherapy (CT) as a reference. MATERIALS AND METHODS: Forty-one leukemia patients (SCT group), 51 lymphoma patients (ASCT group), and 85 CT patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire at baseline and after 1 year. RESULTS: The SCT group (median age, 36 years) had better functioning scores and less symptomatology at baseline compared with the ASCT (median age, 41 years) and CT (median age, 37 years) groups. Statistically significant differences of 10 or more points on the 0 to 100 scales were found for 10 of 15 scales and items (P ≤ .01) between the SCT and ASCT groups. Global quality of life (79 v 58, P < .0001), role function (83 v 65, P = .001), sleep disturbances (6 v 28, P < .0001), and fatigue (25 v 44, P = .0001) deviated most. The differences were 10 or more points for seven of 15 scales and items comparing the SCT and CT groups, with sleep disturbances (6 v 35, P < .0001) and pain (11 v 29, P < .01) deviating most. Differences across groups were smaller after 1 year; cognitive function was the only scale with a statistically significant difference (ASCT 80 v CT 89; P = .002). Patterns of change in HRQOL scores were different between groups during follow-up. A great improvement was found in the ASCT group (P < .01 for emotional and role function, fatigue, appetite, and constipation), whereas no significant changes were observed for the SCT group. CONCLUSION: Prospective studies with extended follow-up periods are necessary to separate a slow recovery process from more permanently reduced HRQOL after transplantation and to examine the late side effects from previous treatment.Keywords
This publication has 23 references indexed in Scilit:
- Quality of life and psychological distress of bone marrow transplant recipients: the ‘time trajectory’ to recovery over the first yearBone Marrow Transplantation, 1998
- Physical and psychosocial functioning in patients undergoing autologous bone marrow transplantation – a prospective studyBone Marrow Transplantation, 1997
- Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trialBone Marrow Transplantation, 1997
- Quality of life following bone marrow transplantation: a comparison of patient reports with population normsBone Marrow Transplantation, 1997
- Comparison of the overall quality of life in 50 long‐term survivors of autologous and allogeneic bone marrow transplantationJournal of Advanced Nursing, 1995
- Quality of life of 125 adults surviving 6–18 years after bone marrow transplantationSocial Science & Medicine, 1995
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- EXTENDED FOLLOW-UP IN 212 LONG-TERM ALLOGENEIC BONE MARROW TRANSPLANT SURVIVORS ISSUES OF QUALITY OF LIFETransplantation, 1993
- ADAPTATION OF ADULT BONE MARROW TRANSPLANT RECIPIENT LONG-TERM SURVIVORSTransplantation, 1986
- The use of the nitrogen mustards in the palliative treatment of carcinoma.With particular reference to bronchogenic carcinomaCancer, 1948